Dr Dilip Surana, CMD of Micro Labs Limited, hails tariff shield as a landmark step that strengthens India’s $9 billion pharma exports to the US, meeting nearly half of America’s generic drug demand while easing patient cost burdens. New Delhi/Washington – The India–US bilateral trade
Recent Posts
- The Sovereign Architects of India’s Digital Century: Top 50 Women IT Leaders
- PoK Gamble: Rhetoric Meets Realpolitik Along the Line of Control
- 4.3 Crore Indians Stranded in Unemployment as Youth Crisis Deepens – Network 7 Research Findings
- Rebuilding Trust: Nandan Nilekani Named Head of High-Powered Task Force to Overhaul India’s Examination System
- The Tectonic Shift: How Student Power Shattered New Delhi’s Doctrine of Absolute Immunity










